D&D Pharmatech tumbles 18% after Pfizer halts ORALINK candidate [K-bio pulse]

D D Pharmatech shares dropped sharply after it was confirmed that development had been halted on an obesity drug candidate built with the company's technology. Coming on the heels of questions about ...